CPRX Catalyst Pharmaceuticals, Inc.
Healthcare$31.33+0.22%ClosedMarket Cap: $3.83B
As of 2026-05-26
Valuation
P/E (TTM)
14.30
PEG
0.46
P/B
3.77
P/S
6.41
EV/EBITDA
9.80
DCF Value
$136.53
FCF Yield
5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
82.3%
Operating Margin
44.8%
Net Margin
37.1%
ROE
23.7%
ROA
19.3%
ROIC
19.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $149.4M | 83.8% | $73.2M | $63.7M | $— | — |
| Q4 null | $152.6M | 82.9% | $61.8M | $52.7M | $— | — |
| FY null | $589.0M | 85.2% | $257.8M | $214.3M | $— | — |
| Q3 null | $148.4M | 82.9% | $66.3M | $52.8M | $— | — |
| Q2 null | $146.6M | 79.6% | $66.3M | $52.1M | $— | — |
| Q1 null | $141.4M | 87.3% | $63.4M | $56.7M | $— | — |
| Q4 null | $141.8M | 84.7% | $62.8M | $55.9M | $— | — |
| FY null | $491.7M | 86.0% | $195.1M | $163.9M | $— | — |
| Q3 null | $128.7M | 85.0% | $50.9M | $43.9M | $— | — |
| Q2 null | $122.7M | 87.4% | $54.2M | $40.8M | $— | — |
| Q1 null | $98.5M | 87.3% | $27.1M | $23.3M | $— | — |
| Q4 2023 | $110.6M | 85.7% | $41.7M | $34.8M | $0.31 | — |